E130203B14Rik Inhibitors
VSTM4, an orthologous gene to human V-set and transmembrane domain-containing 4 (VSTM4), plays a crucial role in multiple cellular processes, acting upstream or within endothelial cell migration, retina blood vessel maintenance, and vasculature development. Positioned in both the extracellular region and plasma membrane, VSTM4 is predicted to be an integral component of the cellular membrane. The intricate involvement of VSTM4 in essential biological processes, particularly those related to vascular development, underscores its significance in maintaining the integrity of the circulatory system.
The targeted inhibition of VSTM4 involves a strategic interference with key signaling pathways and cellular processes associated with its predicted functions. Various chemical inhibitors, such as those targeting TGF-β and VEGF receptors, disrupt the signaling cascades implicated in vasculature development and endothelial cell migration. Inhibition of integrins and focal adhesion kinase (FAK) further impacts cellular processes related to migration, potentially influencing VSTM4 indirectly. Modulation of kinases like ROCK, p38 MAPK, and JNK, through specific inhibitors, offers additional avenues for interference, as these pathways are intricately linked to cellular responses involved in vasculature development. Overall, the inhibition of VSTM4 requires a nuanced understanding of the interconnected signaling pathways and cellular functions in which it participates, providing a foundation for exploring the regulatory mechanisms underlying vascular biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
TGF-β receptor type I (TGFBR1/ALK5) inhibitor. LY364947 impedes TGF-β signaling, potentially influencing VSTM4 indirectly, as TGF-β is involved in various processes, including vasculature development and endothelial cell migration. | ||||||
SU 4312 | 5812-07-7 | sc-200637 sc-200637A | 5 mg 25 mg | $97.00 $360.00 | 2 | |
VEGFR-2 (KDR/Flk-1) inhibitor. SU4312 targets the VEGF receptor, potentially impacting VSTM4 by disrupting VEGF-mediated processes, such as vasculature development and endothelial cell migration. | ||||||
Cilengitide | 188968-51-6 | sc-507335 | 5 mg | $215.00 | ||
Integrin inhibitor. Cilengitide inhibits integrin receptors, affecting endothelial cell migration. Its impact on integrin-mediated processes may indirectly influence VSTM4, as integrins are involved in various cellular functions. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
MEK inhibitor. PD98059 inhibits mitogen-activated protein kinase kinase (MEK), potentially influencing VSTM4 by altering cellular responses in the MAPK pathway, which is implicated in vasculature development. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
TGF-β receptor type I (TGFBR1/ALK5) inhibitor. SB431542 disrupts TGF-β signaling, potentially impacting VSTM4 indirectly, as TGF-β plays a role in vasculature development and endothelial cell migration. | ||||||
SU 6668 | 252916-29-3 | sc-204309 sc-204309A | 10 mg 50 mg | $127.00 $712.00 | 2 | |
Multiple receptor tyrosine kinase inhibitor. SU6668 inhibits multiple tyrosine kinases, affecting pathways involved in vasculature development and endothelial cell migration, potentially influencing VSTM4 indirectly. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Rho-associated protein kinase (ROCK) inhibitor. Y-27632 inhibits ROCK, potentially impacting VSTM4 by modulating cellular processes, including endothelial cell migration, where ROCK is implicated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
p38 MAPK inhibitor. SB203580 targets p38 MAPK, potentially impacting VSTM4 by altering cellular responses in the MAPK pathway, which is involved in vasculature development and endothelial cell migration. | ||||||
VPC 23019 | 449173-19-7 | sc-362817 | 10 mg | $357.00 | 4 | |
ROCK inhibitor. VPC 23019 inhibits ROCK, potentially influencing VSTM4 by modulating cellular processes, including endothelial cell migration, where ROCK plays a role. | ||||||
KI 8751 | 228559-41-9 | sc-203090 | 5 mg | $139.00 | 2 | |
VEGFR-2 (KDR/Flk-1) inhibitor. Ki8751 targets the VEGF receptor, potentially impacting VSTM4 by disrupting VEGF-mediated processes, such as vasculature development and endothelial cell migration. | ||||||